Apellis Positive One-Year Data from Phase 2 Study

 Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced positive one-year results from the Phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.

https://www.globenewswire.com/news-release/2024/05/24/2888033/0/en/Positive-One-Year-Data-from-Phase-2-Study-of-Pegcetacoplan-in-Post-Transplant-Recurrence-of-C3G-and-IC-MPGN-Presented-as-Late-Breaker-at-ERA-Congress.html